Alexion completes Pfizer gene therapy agreement
20 September 2023 Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to